Patents by Inventor Christopher R. Bebbington

Christopher R. Bebbington has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • ANTI-SIGLEC-8 ANTIBODIES AND METHODS OF USE THEREOF
    Publication number: 20220331412
    Abstract: The invention provides humanized anti-Siglec-8 antibodies and their use in treating and preventing eosinophil-mediated disorders and/or mast cell-mediated disorders, as well as compositions and kits comprising the humanized anti-Siglec-8 antibodies.
    Type: Application
    Filed: January 26, 2022
    Publication date: October 20, 2022
    Applicant: Allakos Inc.
    Inventors: Christopher R. BEBBINGTON, Rustom FALAHATI, Carolina Rita SOUSA FERNANDES, David John MATTHEWS, Nenad TOMASEVIC, Jason WILLIAMS, John LEUNG
  • ANTI-SIGLEC-8 ANTIBODIES AND METHODS OF USE THEREOF
    Publication number: 20200054723
    Abstract: The invention provides humanized anti-Siglec-8 antibodies and their use in treating and preventing eosinophil-mediated disorders and/or mast cell-mediated disorders, as well as compositions and kits comprising the humanized anti-Siglec-8 antibodies.
    Type: Application
    Filed: May 17, 2019
    Publication date: February 20, 2020
    Applicant: Allakos Inc.
    Inventors: Christopher R. BEBBINGTON, Rustom FALAHATI, Carolina Rita SOUSA FERNANDES, David John MATTHEWS, Nenad TOMASEVIC, Jason WILLIAMS, John LEUNG
  • Detection of EphA3 as a Marker of the Presence of a Solid Tumor
    Publication number: 20170335001
    Abstract: The invention provides methods and compositions for detecting non-hematopoietic, non-tumor EphA3-expressing cells in cancer patients and for monitoring the prognosis of patients using EphA3.
    Type: Application
    Filed: July 8, 2016
    Publication date: November 23, 2017
    Inventors: Martin Lackmann, Andrew Mark Scott, Catherine To, Christopher R. Bebbington, Geoffrey T. Yarranton, Mark Baer, Varghese Palath
  • Treatment of Leukemias and Chronic Myeloproliferative Diseases with Antibodies to EphA3
    Publication number: 20170226227
    Abstract: The invention provides methods and compositions comprising anti-EphA3 antibodies for the treatment of myeloproliferative disorders.
    Type: Application
    Filed: September 14, 2016
    Publication date: August 10, 2017
    Inventors: Christopher R. Bebbington, Geoffrey T. Yarranton, Varghese Palath
  • ANTI-SIGLEC-8 ANTIBODIES AND METHODS OF USE THEREOF
    Publication number: 20170209556
    Abstract: The invention provides humanized anti-Siglec-8 antibodies and their use in treating and preventing eosinophil-mediated disorders and/or mast cell-mediated disorders, as well as compositions and kits comprising the humanized anti-Siglec-8 antibodies.
    Type: Application
    Filed: December 7, 2016
    Publication date: July 27, 2017
    Applicant: Allakos Inc.
    Inventors: Christopher R. BEBBINGTON, Rustom FALAHATI, Carolina Rita SOUSA FERNANDES, David John MATTHEWS, Nenad TOMASEVIC, Jason WILLIAMS, John LEUNG
  • Anti-Siglec-8 antibodies and methods of use thereof
    Patent number: 9546215
    Abstract: The invention provides humanized anti-Siglec-8 antibodies and their use in treating and preventing eosinophil-mediated disorders and/or mast cell-mediated disorders, as well as compositions and kits comprising the humanized anti-Siglec-8 antibodies.
    Type: Grant
    Filed: December 9, 2014
    Date of Patent: January 17, 2017
    Assignee: ALLAKOS INC.
    Inventors: Christopher R. Bebbington, Rustom Falahati, Carolina Rita Sousa Fernandes, David John Matthews, Nenad Tomasevic, Jason Williams, John Leung
  • Antibodies to EphA3
    Patent number: 9290571
    Abstract: The current invention relates to high-affinity antibodies to EphA3 that have reduced immunogenicity when administered to a human to treat diseases and method of using such antibodies.
    Type: Grant
    Filed: December 30, 2013
    Date of Patent: March 22, 2016
    Assignee: KaloBios Pharmaceuticals, Inc.
    Inventors: Kenneth Luehrsen, David Martinez, Christina Yi, Christopher R. Bebbington, Geoffrey T. Yarranton
  • ANTIBODIES TO GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR
    Publication number: 20150344565
    Abstract: The current invention relates to high-affinity antibodies to Granulocyte-Macrophage Colony-Stimulating Factor that have reduced immunogenicity when administered to a human to treat diseases and method of using such antibodies.
    Type: Application
    Filed: April 2, 2015
    Publication date: December 3, 2015
    Inventors: Christopher R. Bebbington, Kenneth Luehrsen, Geoffrey T. Yarranton
  • Methods of Treating Hematological Proliferative Disorders by Targeting EphA3 Expressed on Aberrant Vasculature in Bone Marrow
    Publication number: 20150329647
    Abstract: The invention provides diagnostic and therapeutic methods for the treatment of hematological proliferative disorders.
    Type: Application
    Filed: July 30, 2015
    Publication date: November 19, 2015
    Inventors: Geoffrey T. Yarranton, Varghese Palath, Christopher R. Bebbington, Mark Baer
  • Secretion of antibodies without signal peptides from bacteria
    Patent number: 9127046
    Abstract: The present invention is directed generally to compositions and methods for obtaining secretion of antibodies or antigen-binding antibody fragments from prokaryotes without the need for a signal peptide through making use of mutant host strains with altered secretory properties. In particular, the invention provides host cells and methods for obtaining secretion of antibodies or antigen-binding antibody fragments from bacteria without the need for a signal peptide and provides diverse libraries of antibody sequence resulting from such methods. The invention additionally provides diverse libraries.
    Type: Grant
    Filed: May 7, 2012
    Date of Patent: September 8, 2015
    Assignee: KaloBios Pharmaceuticals, Inc.
    Inventors: Geoffrey T. Yarranton, Christopher R. Bebbington
  • METHODS OF TREATING CHRONIC INFLAMMATORY DISEASES USING A GM-CSF ANTAGONIST
    Publication number: 20150246121
    Abstract: The invention is based on the discovery that GM-CSF antagonists can be used for the treatment of chronic inflammatory disease, such as rheumatoid arthritis. Accordingly, the invention provides methods of administering a GM-CSF antagonist, e.g., a GM-CSF antibody, and an anti-folate compounds, e.g., methotrexate, to a patient that has RA and pharmaceutical compositions comprising such antagonists.
    Type: Application
    Filed: May 14, 2015
    Publication date: September 3, 2015
    Inventors: Christopher R. Bebbington, Geoffrey T. Yarranton
  • Methods of treating hematological proliferative disorders by targeting EphA3 expressed on aberrant vasculature in bone marrow
    Patent number: 9109032
    Abstract: The invention provides diagnostic and therapeutic methods for the treatment of hematological proliferative disorders.
    Type: Grant
    Filed: August 10, 2012
    Date of Patent: August 18, 2015
    Assignee: KaloBios Pharmaceuticals, Inc.
    Inventors: Geoffrey T. Yarranton, Varghese Palath, Christopher R. Bebbington, Mark Baer
  • ANTI-SIGLEC-8 ANTIBODIES AND METHODS OF USE THEREOF
    Publication number: 20150203578
    Abstract: The invention provides humanized anti-Siglec-8 antibodies and their use in treating and preventing eosinophil-mediated disorders and/or mast cell-mediated disorders, as well as compositions and kits comprising the humanized anti-Siglec-8 antibodies.
    Type: Application
    Filed: December 9, 2014
    Publication date: July 23, 2015
    Applicant: ALLAKOS INC.
    Inventors: CHRISTOPHER R. BEBBINGTON, RUSTOM FALAHATI, CAROLINA RITA SOUSA FERNANDES, DAVID JOHN MATTHEWS, NENAD TOMASEVIC, JASON WILLIAMS, JOHN LEUNG
  • Anti-EMR1 antibodies
    Patent number: 9045539
    Abstract: The invention provides anti-EGF-like module containing, mucin-like, hormone receptor-like 1 (EMR1) antibodies and methods of using such antibodies to treat EMR1-related diseases.
    Type: Grant
    Filed: May 25, 2012
    Date of Patent: June 2, 2015
    Assignee: Kalobios Pharmaceuticals, Inc.
    Inventors: Kenneth Luehrsen, Mark Baer, Christopher R. Bebbington, David Martinez, Varghese Palath, Swathi Sujatha-Bhaskar, Nenad Tomasevic, Jason Williams, Geoffrey T. Yarranton
  • Antibodies to granulocyte-macrophage colony-stimulating factor
    Patent number: 9017674
    Abstract: The current invention relates to high-affinity antibodies to Granulocyte-Macrophage Colony-Stimulating Factor that have reduced immunogenicity when administered to a human to treat diseases and method of using such antibodies.
    Type: Grant
    Filed: April 30, 2012
    Date of Patent: April 28, 2015
    Assignee: KaloBios Pharmaceuticals, Inc.
    Inventors: Christopher R. Bebbington, Kenneth Luehrsen, Geoffrey Yarranton
  • ANTIBODIES TO THE PCRV ANTIGEN OF PSEUDOMONAS AERUGINOSA
    Publication number: 20150030614
    Abstract: The current invention provides high-affinity antibodies to the Pseudomonas aeruginosa PcrV protein that have reduced immunogenicity when administered to treat Pseudomonas aeruginosa infections.
    Type: Application
    Filed: October 8, 2014
    Publication date: January 29, 2015
    Inventors: Christopher R. Bebbington, Kenneth Luehrsen, Geoffrey T. Yarranton, Mark Baer
  • TREATMENT OF LEUKEMIAS AND CHRONIC MYELOPROLIFERATIVE DISEASES WITH ANTIBODIES TO EPHA3
    Publication number: 20140370010
    Abstract: The invention provides methods and compositions comprising anti-EphA3 antibodies for the treatment of myeloproliferative disorders.
    Type: Application
    Filed: August 29, 2014
    Publication date: December 18, 2014
    Inventors: Christopher R. Bebbington, Geoffrey T. Yarranton, Varghese Palath
  • Antibodies to the PcrV antigen of
    Patent number: 8877191
    Abstract: The current invention provides high-affinity antibodies to the Pseudomonas aeruginosa PcrV protein that have reduced immunogenicity when administered to treat Pseudomonas aeruginosa infections.
    Type: Grant
    Filed: October 11, 2011
    Date of Patent: November 4, 2014
    Assignee: KaloBios Pharmaceuticals, Inc.
    Inventors: Christopher R. Bebbington, Kenneth Luehrsen, Geoffrey T. Yarranton, Mark Baer
  • Treatment of leukemias and chronic myeloproliferative diseases with antibodies to EphA3
    Patent number: 8834870
    Abstract: The invention provides methods and compositions comprising anti-EphA3 antibodies for the treatment of myeloproliferative disorders.
    Type: Grant
    Filed: March 5, 2010
    Date of Patent: September 16, 2014
    Assignee: Kalobios Pharmaceuticals, Inc.
    Inventors: Christopher R. Bebbington, Geoffrey T. Yarranton, Varghese Palath
  • Methods for the therapy of inflammatory bowel disease using a type-1 interferon antagonist
    Patent number: 8828393
    Abstract: Compositions and methods for the therapy of Inflammatory Bowel Disease (IBD), including Celiac Disease, Crohn's Disease, and Ulcerative Colitis, are disclosed. Illustrative compositions comprise one or more anti-type 1 interferon antagonists, such as anti-type 1 interferon receptor antibody antagonists and fragments thereof, as well as polypeptides and small molecules that inhibit the interaction of type 1 interferon with its receptor (IFNAR).
    Type: Grant
    Filed: March 17, 2011
    Date of Patent: September 9, 2014
    Assignee: Medarex, L.L.C.
    Inventors: Lesley B. Pickford, Christopher R. Bebbington, Geoffrey T. Yarranton, David King